APIC Publishes New Industry Best Practices Documents - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

APIC Publishes New Industry Best Practices Documents


The Active Pharmaceutical Ingredients Committee (APIC) has published two new documents: Guidance on aspects of cleaning validation in active pharmaceutical ingredients plants and GDP for APIs: “How to do” Document.

Guidance on aspects of cleaning validation in active pharmaceutical ingredients plants: This document is an update of the original guidance on cleaning validation in API manufacturing plants and reflects the outcome of discussions between APIC member companies on how cleaning validation requirements could be fulfilled and implemented as part of routine operations. APIC is also aligning this guidance with the ISPE Risk MaPP Guide that follows the quality risk management processes as described in the ICH Q9 Guidance on Quality Risk Management.
The purpose of this document is to assist companies in the formulation of cleaning validation programs and includes examples of how member companies have dealt with specific areas and issues that arise when performing cleaning validation. It provides a starting point for internal discussions and should not be considered as a technical standard. The topics addressed in this guidance document include acceptance criteria, levels of cleaning, control of the cleaning process, bracketing and worst case rating, determination of the amount of residue, and cleaning validation protocol.
GDP for APIs: “How to do” Document: With the application of GDP for APIs becoming mandatory under the EU Falsified Medicines Directive (Directive 2011/62/EU), this document provides guidance, based on practical experience, on how to implement the Guidelines on the Principles of Active Substances for Medicinal Products for Human Use draft published by the European Commission DG SANCO.
Source: APIC

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here